<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>ETF Trends &#187; BBH</title>
	<atom:link href="http://www.etftrends.com/tag/bbh/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.etftrends.com</link>
	<description>Setting the Pace for Exchange Traded Funds</description>
	<lastBuildDate>Sat, 11 Feb 2012 14:09:57 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Biotech ETFs Break Out</title>
		<link>http://www.etftrends.com/2012/01/biotech-etfs-break-out/</link>
		<comments>http://www.etftrends.com/2012/01/biotech-etfs-break-out/#comments</comments>
		<pubDate>Thu, 19 Jan 2012 14:45:51 +0000</pubDate>
		<dc:creator>John Spence</dc:creator>
				<category><![CDATA[Feature Stories]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=74303</guid>
		<description><![CDATA[The rally in biotechnology exchange traded funds is going vertical in early 2012 with the sector&#8217;s largest ETF posting a gain of 20% over the past three months.
The $1.5 billion iShares Nasdaq Biotechnology Index Fund (IBB) is breaking out to new all-time highs. The ETF is up 9.6% year to date, compared with a 4.1% [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2012/01/biotech-etfs-break-out/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Six HOLDRS Become Van Eck ETFs</title>
		<link>http://www.etftrends.com/2011/12/six-holdrs-become-van-eck-etfs/</link>
		<comments>http://www.etftrends.com/2011/12/six-holdrs-become-van-eck-etfs/#comments</comments>
		<pubDate>Wed, 21 Dec 2011 12:16:48 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[Feature Stories]]></category>
		<category><![CDATA[New ETFs]]></category>
		<category><![CDATA[Banks]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Lead]]></category>
		<category><![CDATA[OIH]]></category>
		<category><![CDATA[Oil]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PPH]]></category>
		<category><![CDATA[Retail]]></category>
		<category><![CDATA[RKH]]></category>
		<category><![CDATA[RTH]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Semiconductors]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[SMH]]></category>
		<category><![CDATA[Technology]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=72136</guid>
		<description><![CDATA[Six Merrill Lynch HOLDRS exchange traded securities stopped trading as planned on Tuesday. The funds were officially transferred and changed into Van Eck Global exchange traded funds, and the new funds will begin trading Wednesday.
Trading in the biotech, banking, oil services, pharmaceuticals, retail and semiconductor HOLDRs halted on Tuesday, according to Van Eck. [HOLDRS Making [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/12/six-holdrs-become-van-eck-etfs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>HOLDRS Making Transition to Market Vector ETFs</title>
		<link>http://www.etftrends.com/2011/11/holdrs-making-transition-to-market-vector-etfs/</link>
		<comments>http://www.etftrends.com/2011/11/holdrs-making-transition-to-market-vector-etfs/#comments</comments>
		<pubDate>Wed, 23 Nov 2011 19:44:41 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[Feature Stories]]></category>
		<category><![CDATA[New ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[ETF 101]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Lead]]></category>
		<category><![CDATA[OIH]]></category>
		<category><![CDATA[Oil & Gas Exploration]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PPH]]></category>
		<category><![CDATA[Retail]]></category>
		<category><![CDATA[RKH]]></category>
		<category><![CDATA[RTH]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Semiconductors]]></category>
		<category><![CDATA[SMH]]></category>
		<category><![CDATA[Technology]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=70305</guid>
		<description><![CDATA[Van Eck Global and Bank of America (NYSE: BAC) subsidiary Merrill Lynch reached an accord on six HOLDRs in August, and now, the transition from the Merrill Lynch HOLDRs to Market Vector exchange traded funds is underway.
An exchange offer for the HOLDRS commenced on Nov. 11 and will run till 11:00 am Eastern time on [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/11/holdrs-making-transition-to-market-vector-etfs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Van Eck, Merrill Lynch in Agreement Over HOLDRS</title>
		<link>http://www.etftrends.com/2011/08/van-eck-merrill-lynch-in-agreement-over-holdrs/</link>
		<comments>http://www.etftrends.com/2011/08/van-eck-merrill-lynch-in-agreement-over-holdrs/#comments</comments>
		<pubDate>Mon, 15 Aug 2011 12:26:15 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[New ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Energy]]></category>
		<category><![CDATA[ETF 101]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[OIH]]></category>
		<category><![CDATA[Oil]]></category>
		<category><![CDATA[Oil & Gas Exploration]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PPH]]></category>
		<category><![CDATA[Retail]]></category>
		<category><![CDATA[RKH]]></category>
		<category><![CDATA[RTH]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Semiconductors]]></category>
		<category><![CDATA[SMH]]></category>
		<category><![CDATA[Technology]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=60671</guid>
		<description><![CDATA[Van Eck Global and Bank of America (NYSE: BAC) subsidiary Merrill Lynch have reached a deal in which Van Eck plans to offer investors in six HOLDRS the chance to swap for shares of new exchange traded funds.

Van Eck filed for six sector-specific ETFs with the Securities and Exchange Commission to issue the Merrill-Lynch HOLDRs [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/08/van-eck-merrill-lynch-in-agreement-over-holdrs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotech ETFs Mixed After Gilead Subpoena</title>
		<link>http://www.etftrends.com/2011/06/biotech-etfs-mixed-after-gilead-subpoena/</link>
		<comments>http://www.etftrends.com/2011/06/biotech-etfs-mixed-after-gilead-subpoena/#comments</comments>
		<pubDate>Mon, 13 Jun 2011 17:53:52 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[PBE]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=56144</guid>
		<description><![CDATA[Biotechnology exchange traded funds were mixed Monday after sector bellwether Gilead Sciences (NasdaqGS: GILD) disclosed it has received a subpoena from the U.S. Department of Justice.
Gilead shares were down nearly 1% but pared their earlier loss after the company late Friday said it has received a request for information from the U.S. Attorney&#8217;s Office for [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/06/biotech-etfs-mixed-after-gilead-subpoena/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biogen Earnings, Drug Data to Lift Biotech ETFs</title>
		<link>http://www.etftrends.com/2011/04/biogen-earnings-drug-data-to-lift-biotech-etfs/</link>
		<comments>http://www.etftrends.com/2011/04/biogen-earnings-drug-data-to-lift-biotech-etfs/#comments</comments>
		<pubDate>Thu, 21 Apr 2011 12:55:22 +0000</pubDate>
		<dc:creator>John Spence</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=51598</guid>
		<description><![CDATA[Biogen (NasdaqGS: BIIB) shares jumped more than 20% in premarket action Thursday after the company reported higher-first quarter profit and released encouraging data on an experimental multiple sclerosis drug.
The data on the drug, BG-12, was “very competitive versus other approved and pipeline MS therapies” and the results are “a significant catalyst for Biogen shares,” said [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/04/biogen-earnings-drug-data-to-lift-biotech-etfs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>5 Biotechnology ETFs to Play Innovation</title>
		<link>http://www.etftrends.com/2011/02/5-biotechnology-etfs-play-innovation/</link>
		<comments>http://www.etftrends.com/2011/02/5-biotechnology-etfs-play-innovation/#comments</comments>
		<pubDate>Tue, 22 Feb 2011 22:00:10 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[HOLDRs]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[PBE]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=46796</guid>
		<description><![CDATA[While the broader market has picked up its pace, the biotechnology sector has not seen a similar surge in performance. Still, investors should keep in mind the various biotech exchange traded fund (ETF) plays to stay positioned for a resurgence in the sector.
Currently, the biotech industry is full of fast-growing and very profitable companies; however, [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/02/5-biotechnology-etfs-play-innovation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Play the Booming Biotech Sector With ETFs</title>
		<link>http://www.etftrends.com/2010/12/play-booming-biotech-sector-etfs/</link>
		<comments>http://www.etftrends.com/2010/12/play-booming-biotech-sector-etfs/#comments</comments>
		<pubDate>Tue, 21 Dec 2010 23:00:29 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[IHE]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=43168</guid>
		<description><![CDATA[Economic downturn? What economic downturn? Despite lackluster economic growth, biotechnology exchange traded funds (ETFs) have managed to notch solid performance this year.
In the United Kingdom alone, the bioscience sector has exploded. It now includes 942 companies, with 345 involved in the development, manufacture or sales of therapeutic products, according to PharmaLive. The biotech sector also [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2010/12/play-booming-biotech-sector-etfs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotech ETFs: 5 Ways to Play Innovation</title>
		<link>http://www.etftrends.com/2010/08/biotech-etfs-5-ways-play-innovation/</link>
		<comments>http://www.etftrends.com/2010/08/biotech-etfs-5-ways-play-innovation/#comments</comments>
		<pubDate>Sun, 08 Aug 2010 20:00:05 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Featured]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[PBE]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=34724</guid>
		<description><![CDATA[Biotechnology has been improving our quality of life for generations. The industry does everything from researching a cure for cancer to finding disease-resistant crops and more. While this can be a difficult sector in which to invest, there are five exchange traded funds (ETFs) that make it easier.
The biotech industry utilizes cellular and biomolecular processes [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2010/08/biotech-etfs-5-ways-play-innovation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>5 Biotech ETFs If You&#8217;re Bullish</title>
		<link>http://www.etftrends.com/2010/06/5-biotech-etfs-if-youre-bullish/</link>
		<comments>http://www.etftrends.com/2010/06/5-biotech-etfs-if-youre-bullish/#comments</comments>
		<pubDate>Fri, 25 Jun 2010 08:00:09 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Featured]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[Feature Stories]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[PBE]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=31834</guid>
		<description><![CDATA[Biotechnology has helped improve the lives of many people. Naturally, many biotech stocks boom or bust based on the success of products in their pipeline. But if you’re looking for a more diversified and steady approach to biotech investing, look no further than exchange traded funds (ETFs).
Matthew D. McCall of Index Universe is bullish on [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2010/06/5-biotech-etfs-if-youre-bullish/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Why Biotech ETFs May Be the Better Choice</title>
		<link>http://www.etftrends.com/2009/06/why-biotech-etfs-may-be-better-choice/</link>
		<comments>http://www.etftrends.com/2009/06/why-biotech-etfs-may-be-better-choice/#comments</comments>
		<pubDate>Wed, 17 Jun 2009 18:00:12 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[PBE]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=11945</guid>
		<description><![CDATA[ Biotechnology stocks present opportunities, but given the unique challenges of the sector, exchange traded funds (ETFs) may be the better route to go if you&#8217;re considering making an investment.
Owning individual biotechnology companies can be a challenging way to invest in the sector, as many of the current companies so not have enough money to [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2009/06/why-biotech-etfs-may-be-better-choice/feed/</wfw:commentRss>
		<slash:comments>7</slash:comments>
		</item>
		<item>
		<title>How Biotech ETFs Can Rise Above Challenges</title>
		<link>http://www.etftrends.com/2009/05/how-biotech-etfs-can-rise-above-challenges/</link>
		<comments>http://www.etftrends.com/2009/05/how-biotech-etfs-can-rise-above-challenges/#comments</comments>
		<pubDate>Tue, 12 May 2009 13:00:11 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[Technology]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=9464</guid>
		<description><![CDATA[In the current economic atmosphere, the biotechnology industry and related exchange traded funds (ETFs) are feeling stressed as investment pullbacks have impeded the sector.
Ernst &#38; Young posted their annual report, which stated that the recession could force companies to consolidate as sources of public funding are diminishing even though the industry was profitable in 2008, [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2009/05/how-biotech-etfs-can-rise-above-challenges/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>How Biotech ETFs Are Overcoming Sector&#8217;s Trials</title>
		<link>http://www.etftrends.com/2009/03/how-biotech-etfs-are-overcoming-sectors-trials/</link>
		<comments>http://www.etftrends.com/2009/03/how-biotech-etfs-are-overcoming-sectors-trials/#comments</comments>
		<pubDate>Tue, 24 Mar 2009 18:00:38 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[Technology]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=8456</guid>
		<description><![CDATA[The biotechnology sector is a place of risky ventures that at times produce lucrative innovations, but the sector and related exchange traded funds (ETFs) need a helping hand in difficult times.
Small biotech companies are courting potential buyers, but not many are large enough to procure the necessary cash to buy them out, reports Kim Hart [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2009/03/how-biotech-etfs-are-overcoming-sectors-trials/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Midday Market Update: Downgrades and Mergers Lead Markets and ETFs</title>
		<link>http://www.etftrends.com/2009/03/midday-market-update-downgrades-mergers-lead-markets-etfs/</link>
		<comments>http://www.etftrends.com/2009/03/midday-market-update-downgrades-mergers-lead-markets-etfs/#comments</comments>
		<pubDate>Thu, 12 Mar 2009 17:00:00 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Retail]]></category>
		<category><![CDATA[XRT]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=8311</guid>
		<description><![CDATA[ General Electric (GE) has been stripped of their AAA credit rating by Standard &#38; Poor&#8217;s, citing troubles within inner-workings,. but exchange traded funds (ETFs) and market are rising above it so far.
GE was cited for the poor performance of their finance unit, however, shares rose 11% as investors prepared for the worst. The Associated [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2009/03/midday-market-update-downgrades-mergers-lead-markets-etfs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>What Stem Cell Research Means for Biotech ETFs</title>
		<link>http://www.etftrends.com/2009/03/what-stem-cell-research-means-biotech-etfs/</link>
		<comments>http://www.etftrends.com/2009/03/what-stem-cell-research-means-biotech-etfs/#comments</comments>
		<pubDate>Tue, 10 Mar 2009 19:00:41 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=8252</guid>
		<description><![CDATA[Will President Barack Obama&#8217;s decision to lift restrictions on stem cell research be beneficial to the biotechnology industry and its exchange traded funds (ETFs)? 
This lift on research restrictions will once again allow researchers to use federal funds to work with new cell lines, however the regulations on creating new stem cell lines remains in [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2009/03/what-stem-cell-research-means-biotech-etfs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

